HIMS, Hers Health Stock

HIMS Earnings Preview: Will The Stock Rebound After 25% Drop?
Hims & Hers Health (NYSE:HIMS) is set to report its earnings on Monday, Feb 24 after market close. HIMS stock plunged over 25% on Friday, Feb 21, after the U.S. FDA announced semaglutide is no longer in shortage.
Why Hims & Hers Health Stock Is Plummeting Today
Shares of Hims & Hers Health (NYSE: HIMS) are falling on Friday. The company's stock lost 23.2% as of 1 p.m. ET and lost as much as 26.1% earlier in the day. The move comes as the S&P 500 lost 1% and the Nasdaq Composite lost 1.
Why Is HIMS Stock Down So Much? Should You Buy?
HIMS stock plunged by 18% after the FDA news that resolved a shortage of weight-loss drugs like Ozempic and Wegovy, which previously allowed Hims & Hers to sell compounded alternatives. Compounded versions were permitted during the shortage but are now restricted unless they meet specific exceptions.
HIMS Stock To Rise >100% Again?
We believe there is minimal cause for concern with HIMS stock, which makes it attractive but highly sensitive to adverse events as its current valuation is extremely
Why Hims & Hers Stock Dropped Today
Raising its price target on the shares to $21, reports The Fly, BofA nonetheless reiterated an "underperform" ( i.e., sell) rating on Hims & Hers stock. Investors are taking the hint, and doing just that.
Hims and Hers Stock Drops Weight as Earnings Loom
Healthcare stock Hims and Hers (HIMS) is sharply lower today but has contrarian potential next week ahead of earnings
What's Going On With Hims & Hers Health Stock Today?
Hims & Hers Health acquired a peptide facility to strengthen its U.S. supply chain and meet demand for personalized treatments. Also, in another development, FDA resolves semaglutide injection shortage.
Why Hims & Hers Health Stock Is Skyrocketing Today
Shares of Hims & Hers Health Inc ( HIMS 17.50%) are flying higher on Wednesday. The company's stock gained 21.7% as of 2:00 p.m. ET, and was up as much as 24.8% earlier in the day. The gain comes as the S&P 500 gained 0.1%, and the Nasdaq Composite was flat.
Hims & Hers Stock Drops as FDA Says Ozempic and Wegovy No Longer in Short Supply
Key Takeaways Hims & Hers Health shares swooned after the Food & Drug Administration said the active ingredient in Ozempic ...
Hims & Hers Declines - How The GLP-1 Market Shift Affects Growth
Hims & Hers plans to launch a generic version of liraglutide, but its efficacy is significantly lower than semaglutide. See ...
Hims & Hers Health (HIMS) Upward Trajectory Boosted by Recent Acquisition
Telehealth pioneer Hims & Hers Health (HIMS) stock is soaring, with a 12% gain in recent days and a whopping 176% in the last ...
Hims & Hers’ 458% Rally Tested as FDA Undercuts Obesity Sales
The blistering rally in Hims & Hers Health Inc. that’s captivated meme-stock traders has ground to a halt, setting up a ...
Hosted on MSN10h
Hims & Hers Retail Traders Eye Robust Post-Earnings Rebound Following Stock’s Worst Drop On Semaglutide Update
Hims & Hers Health Inc. (HIMS) stock tumbled over 25% on Friday, extending losses in after-hours trading after the U.S. Food ...
Hims & Hers stock surges 23%: Telehealth company announces expansion into blood testing weeks after Super Bowl buzz
Hims’s acquisition of Trybe Labs will put it in competition with health industry juggernauts such as Labcorp and Quest ...
Analysts explain why Hims & Hers stock is crashing today
On Friday, shares of Hims&Hers Health Inc (NYSE:HIMS) dropped over 20% following an FDA announcement that the supply shortage of Novo Nordisk (NYSE:NVO)'s weight loss and diabetes drugs was ending.
Hims & Hers Health: The Ultimate Pick For The Next Decade
Hims & Hers Health, Inc. is a dramatically undervalued company if your holding period can be measured in decades. Read more ...